0001375151-19-000090.txt : 20190705
0001375151-19-000090.hdr.sgml : 20190705
20190705191207
ACCESSION NUMBER: 0001375151-19-000090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190703
FILED AS OF DATE: 20190705
DATE AS OF CHANGE: 20190705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FARR STEPHEN J
CENTRAL INDEX KEY: 0001247666
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 19944108
MAIL ADDRESS:
STREET 1: SFARR@ZOGENIX.COM
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 550-8300
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
4
1
wf-form4_156236831121942.xml
FORM 4
X0306
4
2019-07-03
0
0001375151
ZOGENIX, INC.
ZGNX
0001247666
FARR STEPHEN J
C/O ZOGENIX, INC.
5959 HORTON STREET, SUITE 500
EMERYVILLE
CA
94608
1
1
0
0
President and CEO
Common Stock
2019-07-03
4
M
0
9375
32
A
64533
D
Common Stock
2019-07-03
4
M
0
787
10.35
A
65320
D
Common Stock
2019-07-03
4
M
0
24063
10.20
A
89383
D
Common Stock
2019-07-03
4
S
0
14353
47.7996
D
75030
D
Common Stock
2019-07-03
4
S
0
19872
48.1629
D
55158
D
Stock Option (Right to Buy)
32.0
2019-07-03
4
M
0
9375
0
D
2020-05-25
Common Stock
9375.0
3125
D
Stock Option (Right to Buy)
10.35
2019-07-03
4
M
0
787
0
D
2026-03-13
Common Stock
787.0
164212
D
Stock Option (Right to Buy)
10.2
2019-07-03
4
M
0
24063
0
D
2027-03-13
Common Stock
24063.0
85937
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
Includes 443 shares acquired under the Company's Employee Stock Purchase Plan since the last Section 16 filing by the reporting person.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $47.41 to $47.99, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $48.00 to $48.70, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Option was granted on 5/25/2010. 1/4th of the shares subject to the option vested and became exercisable on May 25, 2011 and 1/48th of the shares subject to the option vests monthly thereafter.
Option was granted on 3/14/2016. 1/48th of the shares subject to the option vested and became exercisable on April 14, 2016 and 1/48th of the shares subject to the option vests monthly thereafter, subject to the reporting person's continued service to the Company on the applicable vesting dates.
Option was granted on 3/14/2017. 1/48th of the shares subject to the option vested and became exercisable on April 14, 2017 and 1/48th of the shares subject to the option vests monthly thereafter, subject to the reporting person's continued service to the Company on the applicable vesting dates.
/s/ Thomas Doyle, Attorney-in-fact for Stephen Farr
2019-07-05